APPLICATION
ANDA211004
TYPE
ANDA
ORIGINAL APPROVAL
2020-02-24
LATEST ACTION
2026-02-20
ROUTE
INTRAVENOUS, SUBCUTANEOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription
Products
HEPARIN SODIUMPrescription
HEPARIN SODIUM 20,000 UNITS/ML · INJECTABLE · INJECTION
Approval history
2026-02-20Labeling · Supplement 9 · standardAP
2021-10-25Labeling · Supplement 4 · standardAP
2020-09-29Labeling · Supplement 3 · standardAP
2020-02-24UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.